Hello Everyone,
The stock (PULM) experienced rapid growth (bull) within today's market. Considering the current sporadic momentum upwards, there is none-the-less an opportunity to short the stock till price consolidation.
Resistance Level 1 - (4.30 - 4.50) 20 pip interval
Blue Horizontal Line - (1.80 - 2.10) 30 pip interval
Support Level 1 - (0.50 - 0.80) 30...
Pulmatrix Drug Candidate Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA
The FDA designation adds five years of market exclusivity for Pulmatrix' inhaled product for treating fungal infections in the lungs of CF patients
Under the QIDP program, which is designed to speed the development of novel drugs against important pathogens,...
been watching pulm for continuation and we have nice volume confirmation on the pivots with breakout, retesting breakout line and 50dma stock should go higher
Pulmatrix Inc. (PULM) develops therapies for the treatment of pulmonary diseases. It came public above $20 in March 2014 and entered a severe downtrend that continued into the start of 2017, dropping to an all-time low at 50-cents. The stock went vertical in early February, after meeting Nasdaq exchange compliance issues, and stalled following a 950K secondary...
If we break the support box ( 3.18-3.05 ) , we will sell short to the 1.81
if the price hit the support box and pull back , he may retouch the top and making some double top
PULM has been a monster these past few days kept a close on it during the open and scalped the 5 break. Sold half and rode the rest to 6 and didnt touch it. Alot of the other students bought this big dips at 10 and 1030 but we advised to get out after 12 has there was a change in trend.
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
PULM
